CA2885688C - Combination of regorafenib and acetylsalicylic acid for treating cancer - Google Patents
Combination of regorafenib and acetylsalicylic acid for treating cancer Download PDFInfo
- Publication number
- CA2885688C CA2885688C CA2885688A CA2885688A CA2885688C CA 2885688 C CA2885688 C CA 2885688C CA 2885688 A CA2885688 A CA 2885688A CA 2885688 A CA2885688 A CA 2885688A CA 2885688 C CA2885688 C CA 2885688C
- Authority
- CA
- Canada
- Prior art keywords
- combination
- regorafenib
- acid
- acetylsalicylic acid
- limited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185852 | 2012-09-25 | ||
| EP12185852.6 | 2012-09-25 | ||
| PCT/EP2013/069735 WO2014048881A1 (en) | 2012-09-25 | 2013-09-23 | Combination of regorafenib and acetylsalicylic acid for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2885688A1 CA2885688A1 (en) | 2014-04-03 |
| CA2885688C true CA2885688C (en) | 2021-03-02 |
Family
ID=46963566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2885688A Active CA2885688C (en) | 2012-09-25 | 2013-09-23 | Combination of regorafenib and acetylsalicylic acid for treating cancer |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10898500B2 (pt-PT) |
| EP (1) | EP2900269B1 (pt-PT) |
| JP (1) | JP6294888B2 (pt-PT) |
| KR (1) | KR102210575B1 (pt-PT) |
| CN (1) | CN104994876A (pt-PT) |
| AU (1) | AU2013322854B2 (pt-PT) |
| BR (1) | BR112015006686B1 (pt-PT) |
| CA (1) | CA2885688C (pt-PT) |
| CL (1) | CL2015000744A1 (pt-PT) |
| CY (1) | CY1120939T1 (pt-PT) |
| DK (1) | DK2900269T3 (pt-PT) |
| EA (1) | EA032023B1 (pt-PT) |
| ES (1) | ES2687985T3 (pt-PT) |
| HK (1) | HK1214169A1 (pt-PT) |
| HR (1) | HRP20181462T1 (pt-PT) |
| HU (1) | HUE039878T2 (pt-PT) |
| IL (1) | IL237690B (pt-PT) |
| LT (1) | LT2900269T (pt-PT) |
| MX (1) | MX357035B (pt-PT) |
| MY (1) | MY183969A (pt-PT) |
| NZ (1) | NZ705860A (pt-PT) |
| PH (1) | PH12015500587A1 (pt-PT) |
| PL (1) | PL2900269T3 (pt-PT) |
| PT (1) | PT2900269T (pt-PT) |
| RS (1) | RS57875B1 (pt-PT) |
| SG (2) | SG11201501963RA (pt-PT) |
| SI (1) | SI2900269T1 (pt-PT) |
| WO (1) | WO2014048881A1 (pt-PT) |
| ZA (1) | ZA201502840B (pt-PT) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013276617B9 (en) | 2012-06-13 | 2018-03-29 | F. Hoffmann-La Roche Ag | New diazaspirocycloalkane and azaspirocycloalkane |
| SI2900669T1 (sl) | 2012-09-25 | 2019-12-31 | F. Hoffmann-La Roche Ag | Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| MY187449A (en) | 2013-11-26 | 2021-09-22 | Hoffmann La Roche | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
| PE20161223A1 (es) | 2014-03-26 | 2016-11-12 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
| DK3122750T3 (da) | 2014-03-26 | 2019-11-04 | Hoffmann La Roche | Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere |
| CN103923001B (zh) * | 2014-04-30 | 2016-02-10 | 药源药物化学（上海）有限公司 | 瑞戈非尼盐及其晶型、制备方法 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| JP6886967B2 (ja) | 2015-09-04 | 2021-06-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | フェノキシメチル誘導体 |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| MA42923A (fr) | 2015-09-24 | 2021-04-28 | Hoffmann La Roche | Composés bicycliques comme inhibiteurs mixtes de atx/ca |
| CN107614505B (zh) | 2015-09-24 | 2021-05-07 | 豪夫迈·罗氏有限公司 | 作为双重atx/ca抑制剂的新型二环化合物 |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112018006024A2 (pt) | 2015-09-24 | 2020-05-12 | F. Hoffmann-La Roche Ag | Compostos bicíclicos como inibidores de atx |
| KR102397334B1 (ko) * | 2016-06-28 | 2022-05-11 | 아사메딕 에이에스 | 2성분 조성물 |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| PT3630112T (pt) | 2017-06-02 | 2024-04-23 | Bayer Healthcare Llc | Combinação de regorafenib e nivolumab para tratamento de cancro |
| EP3501522A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Compositions comprising acetylsalicylic acid and a phosphate salt |
| EP3501523A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Two-component compositions comprising acetyl salicylic acid and a carbonate salt |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1197228A4 (en) * | 1999-07-02 | 2004-03-10 | Hisamitsu Pharmaceutical Co | DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER |
| US20040121004A1 (en) | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| DK1663978T3 (da) * | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| CA2628881A1 (en) * | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl urea for treating diabetic neuropathy |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| GB201002530D0 (en) * | 2010-02-15 | 2010-03-31 | Univ Wolverhampton The | Di-aspirin derivatives |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
-
2013
- 2013-09-23 SG SG11201501963RA patent/SG11201501963RA/en unknown
- 2013-09-23 ES ES13770659.4T patent/ES2687985T3/es active Active
- 2013-09-23 KR KR1020157010519A patent/KR102210575B1/ko active IP Right Grant
- 2013-09-23 AU AU2013322854A patent/AU2013322854B2/en active Active
- 2013-09-23 MY MYPI2015700911A patent/MY183969A/en unknown
- 2013-09-23 PL PL13770659T patent/PL2900269T3/pl unknown
- 2013-09-23 JP JP2015532437A patent/JP6294888B2/ja active Active
- 2013-09-23 SG SG10201702356VA patent/SG10201702356VA/en unknown
- 2013-09-23 PT PT13770659T patent/PT2900269T/pt unknown
- 2013-09-23 EA EA201500365A patent/EA032023B1/ru not_active IP Right Cessation
- 2013-09-23 SI SI201331181T patent/SI2900269T1/sl unknown
- 2013-09-23 BR BR112015006686-0A patent/BR112015006686B1/pt active IP Right Grant
- 2013-09-23 CN CN201380050150.7A patent/CN104994876A/zh active Pending
- 2013-09-23 MX MX2015003728A patent/MX357035B/es active IP Right Grant
- 2013-09-23 HU HUE13770659A patent/HUE039878T2/hu unknown
- 2013-09-23 NZ NZ705860A patent/NZ705860A/en unknown
- 2013-09-23 DK DK13770659.4T patent/DK2900269T3/en active
- 2013-09-23 US US14/431,119 patent/US10898500B2/en active Active
- 2013-09-23 CA CA2885688A patent/CA2885688C/en active Active
- 2013-09-23 RS RS20181015A patent/RS57875B1/sr unknown
- 2013-09-23 EP EP13770659.4A patent/EP2900269B1/en active Active
- 2013-09-23 WO PCT/EP2013/069735 patent/WO2014048881A1/en active Application Filing
- 2013-09-23 LT LTEP13770659.4T patent/LT2900269T/lt unknown
-
2015
- 2015-03-12 IL IL237690A patent/IL237690B/en active IP Right Grant
- 2015-03-17 PH PH12015500587A patent/PH12015500587A1/en unknown
- 2015-03-24 CL CL2015000744A patent/CL2015000744A1/es unknown
- 2015-04-24 ZA ZA2015/02840A patent/ZA201502840B/en unknown
-
2016
- 2016-03-01 HK HK16102326.3A patent/HK1214169A1/zh unknown
-
2018
- 2018-09-12 HR HRP20181462TT patent/HRP20181462T1/hr unknown
- 2018-09-20 CY CY181100976T patent/CY1120939T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2885688C (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| US20100113533A1 (en) | Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide | |
| JP7475402B2 (ja) | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 | |
| RU2774838C2 (ru) | Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака | |
| WO2021160708A1 (en) | Combination of regorafenib and msln-ttc for treating cancer | |
| JP2024096905A (ja) | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180913 |